Medivir AB (STO:MVIR), a pharmaceutical company with a focus on oncology, announced on Monday the appointment of Dr Uli Hacksell as the company's acting CEO, effective immediately, to concentrate its activities on clinical development.

Dr Hacksell succeeds Christine Lind.

Currently, Dr Hacksell serves on the board of directors of Medivir, a position he has held since 3 May 2018. Prior to that, he held senior positions in major pharmaceutical and biotech companies for over 25 years and has more than 10 years' experience as the CEO of publicly owned companies. He also served as CEO of ACADIA Pharmaceuticals from 2000 to 2015. In the 1990s, he held senior positions at Astra AB, prior to which he was a Professor of Organic Chemistry at Uppsala University.

Currently, Medivir's clinical pipeline consists of the four projects of remetinostat for cutaneous T-cell lymphoma (phase II), birinapant in combination with Keytrudaâfor solid tumours (phase I), MIV-818, a nucleotide prodrug for liver cancer that recently entered into a phase I clinical trial and MIV-711, an osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study.